Tetrandrine for Targeting Therapy Resistance in Cancer

Overview

Journal Curr Top Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2024 Mar 6

PMID 38445699

Authors

Ellen Nogueira Lima

Santosh Lamichhane

K C Pramod Bahadur

Elisa Silva Ferreira

Sweaty Koul

Hari K Koul

Affiliations

Soon will be listed here.

Abstract

During the last five decades, there has been tremendous development in our understanding of cancer biology and the development of new and novel therapeutics to target cancer. However, despite these advances, cancer remains the second leading cause of death across the globe. Most cancer deaths are attributed to the development of resistance to current therapies. There is an urgent and unmet need to address cancer therapy resistance. Tetrandrine, a bis-benzyl iso-quinoline, has shown a promising role as an anti-cancer agent. Recent work from our laboratory and others suggests that tetrandrine and its derivatives could be an excellent adjuvant to the current arsenal of anti-cancer drugs. Herein, we provide an overview of resistance mechanisms to current therapeutics and review the existing literature on the anti-cancer effects of tetrandrine and its potential use for overcoming therapy resistance in cancer.

References

Cavalcante G, Schaan A, Fonseca Cabral G, Santana-da-Silva M, Pinto P, Vidal A . A Cell's Fate: An Overview of the Molecular Biology and Genetics of Apoptosis. Int J Mol Sci. 2019; 20(17). PMC: 6747454. DOI: 10.3390/ijms20174133. View

Vasiliou V, Vasiliou K, Nebert D . Human ATP-binding cassette (ABC) transporter family. Hum Genomics. 2009; 3(3):281-90. PMC: 2752038. DOI: 10.1186/1479-7364-3-3-281. View

Lee C, Gottesman M . HIV-1 protease inhibitors and the MDR1 multidrug transporter. J Clin Invest. 1998; 101(2):287-8. PMC: 508565. DOI: 10.1172/JCI2575. View

Ashkenazi A . Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002; 2(6):420-30. DOI: 10.1038/nrc821. View

Wall M, Wani M . Antineoplastic agents from plants. Annu Rev Pharmacol Toxicol. 1977; 17:117-32. DOI: 10.1146/annurev.pa.17.040177.001001. View

Zhao Y, Wang L, Ma C, Zhao K, Liu Y, Feng N . Preparation and characterization of tetrandrine-phospholipid complex loaded lipid nanocapsules as potential oral carriers. Int J Nanomedicine. 2013; 8:4169-81. PMC: 3817030. DOI: 10.2147/IJN.S50557. View

Ward R, Fawell S, Floch N, Flemington V, McKerrecher D, Smith P . Challenges and Opportunities in Cancer Drug Resistance. Chem Rev. 2020; 121(6):3297-3351. DOI: 10.1021/acs.chemrev.0c00383. View

Fu L, Liang Y, Deng L, Ding Y, Chen L, Ye Y . Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Chemother Pharmacol. 2003; 53(4):349-56. DOI: 10.1007/s00280-003-0742-5. View

Baratchian M, Tiwari R, Khalighi S, Chakravarthy A, Yuan W, Berk M . H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer. Proc Natl Acad Sci U S A. 2022; 119(21):e2114324119. PMC: 9173765. DOI: 10.1073/pnas.2114324119. View

10.

Liu C, Lv L, Guo W, Mo L, Huang Y, Li G . Self-Nanoemulsifying Drug Delivery System of Tetrandrine for Improved Bioavailability: Physicochemical Characterization and Pharmacokinetic Study. Biomed Res Int. 2018; 2018:6763057. PMC: 6180989. DOI: 10.1155/2018/6763057. View

11.

Santamaria P, Moreno-Bueno G, Cano A . Contribution of Epithelial Plasticity to Therapy Resistance. J Clin Med. 2019; 8(5). PMC: 6571660. DOI: 10.3390/jcm8050676. View

12.

Chang K, Liao H, Chang H, Chen Y, Yu M, Chou C . Inhibitory effect of tetrandrine on pulmonary metastases in CT26 colorectal adenocarcinoma-bearing BALB/c mice. Am J Chin Med. 2005; 32(6):863-72. DOI: 10.1142/S0192415X04002478. View

13.

Zhang R, Wang S, Zhang H, Lan J, Xu G, Zhao Y . Discovery of tetrandrine derivatives as tumor migration, invasion and angiogenesis inhibitors. Bioorg Chem. 2020; 101:104025. DOI: 10.1016/j.bioorg.2020.104025. View

14.

Liu C, Gong K, Mao X, Li W . Tetrandrine induces apoptosis by activating reactive oxygen species and repressing Akt activity in human hepatocellular carcinoma. Int J Cancer. 2010; 129(6):1519-31. DOI: 10.1002/ijc.25817. View

15.

Selvakumar S, Preethi K, Sekar D . MicroRNAs as important players in regulating cancer through PTEN/PI3K/AKT signalling pathways. Biochim Biophys Acta Rev Cancer. 2023; 1878(3):188904. DOI: 10.1016/j.bbcan.2023.188904. View

16.

Schutz R, Muller M, Geisslinger F, Vollmar A, Bartel K, Bracher F . Synthesis, biological evaluation and toxicity of novel tetrandrine analogues. Eur J Med Chem. 2020; 207:112810. PMC: 7473156. DOI: 10.1016/j.ejmech.2020.112810. View

17.

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B . The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017; 7(3):339-348. PMC: 5651054. DOI: 10.15171/apb.2017.041. View

18.

Wang Y, Yue W, Lang H, Ding X, Chen X, Chen H . Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine. Integr Cancer Ther. 2021; 20:1534735421996822. PMC: 8164553. DOI: 10.1177/1534735421996822. View

19.

Wang T, Wan J, Gong X, Li H, Cheng Y . Tetrandrine enhances cytotoxicity of cisplatin in human drug-resistant esophageal squamous carcinoma cells by inhibition of multidrug resistance-associated protein 1. Oncol Rep. 2012; 28(5):1681-6. DOI: 10.3892/or.2012.1999. View

20.

Xu W, Wang X, Chen S, Wu H, Tanaka S, Onda K . Tetrandrine enhances glucocorticoid receptor translocation possibly via inhibition of P-glycoprotein in daunorubicin-resistant human T lymphoblastoid leukemia cells. Eur J Pharmacol. 2020; 881:173232. DOI: 10.1016/j.ejphar.2020.173232. View